Stock Report: EXACT Sciences Corp. (EXAS) Report Updated: May 13, 2013 | Print This Page

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect each of the four stages of colorectal cancer, as well as pre-cancerous lesions. Its test includes proprietary and patented methods, which isolate and analyze the trace amounts of human DNA that are shed into stool every day from the exfoliation of cells that line the colon. The company’s Cologuard test is also used to detect blood in stool, utilizing an antibody-based fecal immunochemical test. It has a strategic alliance agreement with LabCorp under which it licenses its patents and patent applications relating to the stool-based colorectal cancer screening technology to LabCorp; a collaboration, license, and purchase agreement with Genzyme Corporation to deliver intellectual property improvements through licenses; and a license agreement with MAYO Foundation for medical education and research. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.